NASDAQ · QURE
uniQure N.V.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for QURE: Nov 04, 2026
uniQure N.V. Ordinary Shares is expected to report earnings on 11/04/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.84. The reported EPS for the same quarter last year was $-1.38.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.84 | $-0.70 | $-1.01 | 4 |
| Dec 2026 | $-0.89 | $-0.75 | $-1.05 | 4 |
| Mar 2027 | $-1.05 | $-1.04 | $-1.06 | 2 |
| Jun 2027 | $-1.07 | $-1.07 | $-1.07 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Barchart · Zacks · MarketBeat · RTTNews- Barchart · Sep 30, 1:34 PM EDTStocks Settle Mixed as Bond Yields RiseThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.17% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.21%. December E-mini S&P futures (ESZ26 ) fell -0.15%, and December E-mini…
- Zacks · Sep 30, 12:47 PM EDTuniQure Plunges on Additional Data From Huntington's Disease StudyQURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
- Barchart · Sep 29, 7:19 PM EDTStocks Turn Mixed as Bond Yields RiseThe S&P 500 Index ($SPX ) (SPY ) is down by -0.11% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.24%. December E-mini S&P futures (ESZ26 ) are down -0.18%, and December E-mini…
- Barchart · Sep 29, 6:05 PM EDTStocks Rebound as Crude Prices Fall and Bond Yields StabilizeThe S&P 500 Index ($SPX ) (SPY ) is up by +0.03% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.10%. December E-mini S&P futures (ESZ26 ) are up +0.05%, and December E-mini…
- MarketBeat · Sep 29, 4:02 PM EDTuniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional BenefitBreakout Momentum Plays You Need to Know AboutuniQure (NASDAQ:QURE) reported updated Phase I/II data for its investigational Huntington’s disease gene therapy, ifezuntirgene inilparvovec, or AMT-130, including 36-month results from all high-dose patients and 48-month results from
- RTTNews · Sep 29, 12:46 PM EDTUniQure Stock Falls 37% After Huntington's Disease Trial Update(RTTNews) – Shares of uniQure N.V. (QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington's disease.
- RTTNews · Sep 29, 9:44 AM EDTUniQure Reports Four-Year AMT-130 Data In Huntington's Disease; Stock Down(RTTNews) – uniQure (QURE) reported additional data from its ongoing Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) for the treatment of Huntington's disease.
- RTTNews · Sep 29, 9:04 AM EDTUniQure's AMT-130 Shows Continued Slowing Of Huntington's Disease Progression(RTTNews) – Tuesday, uniQure (QURE) reported new data showing its investigational gene therapy AMT-130 continued to slow measures of Huntington's disease progression in patients followed for up to 48 months.
- Zacks · Sep 3, 11:30 AM EDTSpyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Sep 3, 10:30 AM EDTQURE Submits Application for Gene Therapy for Huntington's DiseaseQURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
- RTTNews · Sep 2, 7:38 AM EDTUniQure Submits Biologics License Application For AMT-130 In Huntington's Disease; Stock Up(RTTNews) – uniQure N.V. (QURE) announced that it has submitted a Biologics License Application to the U.S. FDA seeking accelerated approval for ifezuntirgene inilparvovec.
- Zacks · Aug 28, 11:30 AM EDTWhy Is uniQure (QURE) Up 17.5% Since Last Earnings Report?uniQure (QURE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for uniQure N.V. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.